75726-96-4

Basic information

• Product Name: 2-bromo-N-isopropylacetamide
• Synonyms: 2-bromo-N-isopropylacetamide;acetamide, 2-bromo-N-(1-methylethyl)-;2-bromo-N-isopropylacetamide(SALTDATA: FREE);2-Bromo-N-(1-methylethyl)-acetamide;N-(Bromoacetyl)isopropylamine;2-broMo-N-(propan-2-yl)acetaMide
• CAS NO: 75726-96-4
• Molecular Formula: C₅H₁₀BrNO
• Molecular Weight: 180.05
• Mol File: 75726-96-4.mol
• Article Data: 17

Chemical Properties

• Melting Point: 63-64℃
• Boiling Point: 266℃
• Flash Point: 115℃
• Appearance: /
• Density: 1.378
• Vapor Pressure: 0.009mmHg at 25°C
• Refractive Index: 1.472
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 13.71±0.46(Predicted)
• CAS DataBase Reference: 2-bromo-N-isopropylacetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-N-isopropylacetamide(75726-96-4)
• EPA Substance Registry System: 2-bromo-N-isopropylacetamide(75726-96-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 75726-96-4(Hazardous Substances Data)

Usage

General Description

2-Bromo-N-isopropylacetamide is a chemical compound that belongs to the class of amides and isopropyl compounds. It is typically used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. The presence of the bromo group makes this compound a valuable building block in organic synthesis, allowing for the introduction of diverse functional groups through substitution reactions. Additionally, the isopropyl group provides steric hindrance, which can influence the reactivity and selectivity of certain reactions. Overall, 2-Bromo-N-isopropylacetamide plays a crucial role in the production of various pharmaceutical and organic products due to its versatile chemical properties.

InChI:InChI=1/C5H10BrNO/c1-4(2)7-5(8)3-6/h4H,3H2,1-2H3,(H,7,8)

Upstream product

• 75-31-0 isopropylamine 
• 598-21-0 2-Bromoacetyl bromide 
• 71985-62-1 2-benzenesulfonyl-2-bromo-1-isopropyl-aziridine 
• 22118-09-8 2-bromoacetyl chloride 
• 79-08-3 bromoacetic acid 

Downstream Products

• 38265-81-5 Dithiophosphoric acid O-ethyl ester S-(isopropylcarbamoyl-methyl) ester S'-(2-methoxy-ethyl) ester 
• 38265-82-6 Dithiophosphoric acid S-(2-ethoxy-ethyl) ester O-ethyl ester S'-(isopropylcarbamoyl-methyl) ester 
• 151965-03-6 2-Benzyloxyamino-N-isopropyl-acetamide 
• 104241-10-3 C₅₉H₉₁N₁₈O₂₂S₃⁽¹⁺⁾*HO₄S^(1-) 
• 51489-14-6 N-isopropyl-2-methylamino-acetamide 
• 496018-68-9 GTC-268925 
• 445266-27-3 GTC-268776 
• 865255-94-3 [(N'-tert-butylureayl)-N-ethyl]-bis(N''-isopropylcarbamoyl-methyl)-amine 
• 865255-93-2 bis[(N'-tert-butylureayl)-N-ethyl]-(N''-isopropylcarbamoyl-methyl)amine 
• 710355-36-5 1,2-dimethyl-3-(2-propyl)imidazolidin-4-one 
• 151965-00-3 Piv-Proψα(O^βBzl)>Gly-NHiPr 
• 329279-30-3 1,4-bis(N-isopropylacetamid)-7-ethyl-1,4,7-triazacyclononane 
• 911417-95-3 tert-butyl 5-(2-(3-(2-(isopropylamino)-2-oxoethoxy)phenyl)quinazolin-4-ylainino)-1H-indazole-1-carboxylate 
• 1039749-45-5 (+/-)-4,4-dicyano-1-isopropyl-5-phenylpyrrolidin-2-one 

Relevant articles and documents

In Vitro Anti-Toxoplasma gondii Activity Evaluation of a New Series of Quinazolin-4(3H)-one Derivatives

Toxoplasmosis post serious threaten to human health, leading to severely eye and brain disease, especially for immunocompromised patients and pregnant women. The multiple side effects and long dosing period of current main treatment regiments calls for high effective and low toxicity anti-toxoplasmosis drugs. Herein, we report our efforts to synthesize a series of 2-(piperazin-1-yl)quinazolin-4(3H)-one derivatives and investigate their activity against Toxoplasma gondii tachyzoites in vitro based on cell phenotype screening. Among the 26 compounds, 8w and 8x with diaryl ether moiety at the side chain of piperazine exhibited good efficacy to inhibit T. gondii, with IC50 values of 4 μM and 3 μM, respectively. Structure-activity relationship (SAR) studies implies that hydrophobic aryl at the side chain would be preferred for improvement of activity. Molecular docking study reveals these two compounds appeared high affinity to TgCDPK1 by interaction with the hydrophobic pocket of ATP-binding cleft.

TREATMENT OF GVHD

The invention relates to treatment of graft versus host disease (GVHD) using compounds that inhibit ROCK2. In preferred aspects, the present invention provides methods for the treatment of GVHD, including chronic GVHD ( cGVHD) using compounds having the formulae l-XXV, as set forth herein.

TREATMENT OF OCULAR DISORDERS

The invention provides methods of treatment of ocular disorders, including ocular disease with an angiogenic component. In certain embodiments, the treatment comprises administration of a ROCK2 inhibitor and an angiogenesis inhibitor. In certain embodiments, the ROCK2 inhibitor is ROCK2 selective. In certain embodiments, the angiogenesis inhibitor is a VEGF antagonist, for example, and VEGFR2 antibody.